NCT00689884终止不适用
A Prospective Feasibility and Cost Analysis of Peripheral Blood Stem Cell Mobilization Using Pegfilgrastim in Patients With Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Efficacy of Pegfilgrastim in the Mobilization of Autologous Peripheral Blood Stem Cells (PBSCs), Defined as Cell Yield ≥ 3 x 10e6 CD34+/kg
研究概览
简要总结
The purpose of this study is to determine the efficacy of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells (PBSCs), defined as cell yield ≥ 3 x 10e6 CD34+/kg and to assess the costs related to Pegfilgrastim use in the mobilization of autologous PBSCs. Also to determine the side effects of Pegfilgrastim in the mobilization of autologous peripheral blood stem cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients with hematologic malignancies undergoing stem cell mobilization in association with chemotherapy, prior to autologous stem cell transplantation.
- •Prior Treatment:No parenteral cytotoxic chemotherapy within 2 weeks prior to initiation of chemo-mobilization therapy.
- •Performance Status: Karnofsky > 70%
- •Life Expectancy > 4 months
- •Bone Marrow: bone marrow biopsy and aspirate
- •Blood counts: The patient must have adequate bone marrow function, i.e. a total WBC of > 2,000/ul, a Hgb of > 7 g/dl, and a platelet count of > 50,000/ul, unless this abnormality is believed to be due to the underlying disease.
- •Pulmonary function tests: DLCO > 55% predicted.
- •Cardiac: Left ventricular ejection fraction of > 40% by radionuclide scan or echocardiography.
- •Liver function tests (bilirubin, alkaline phosphatase, and SGOT/SGPT) < 3 x normal (unless believed to be elevated due to disease).
- •Renal function (24 hour urine for creatinine clearance, if clinically indicated): The patient must have adequate renal function (creatinine clearance >50 ml/min), except when renal insufficiency is felt related to the underlying malignancy.
- •No significant co-morbid medical or psychiatric illness that would significantly compromise the patient's clinical care and chances of survival in the transplant setting.
- •No significant established splenomegaly (i.e. spleen size > 20 cm)
- •Informed written consent must be obtained. Patients must be able to give informed consent as a prerequisite to this procedure. The Informed Consent form will become part of his/her permanent record and a copy will be given to the patient.
排除标准
- •Patients with greater than three pre-transplant chemotherapy regimens and/or poor stem cell reserve as demonstrated by significant marrow hypocellularity (<20%) will not be mobilized on the first phase regimen
- •Medical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapy.
- •Evidence on physical exam, LP, CT, or MRI scan of CNS involvement with malignancy.
- •Uncontrolled or severe cardiovascular disease, including recent (< 6 months) myocardial infarction, congestive heart failure, angina (symptomatic despite optimal medical management), life-threatening dysrhythmia, or clinically significant obstructive/restrictive pulmonary disease.
- •Serology positive for HIV.
- •Positive pregnancy test or presence of lactation.
- •Uncontrolled active infection.
- •Documented hypersensitivity to any of the drugs used in the protocol.
- •No concomitant,ongoing malignancy that is life-threatening, based on PI's evaluation.
研究组 & 干预措施
Group A
Experimental
All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
干预措施: Pegfilgrastim (Drug)
结局指标
主要结局
Efficacy of Pegfilgrastim in the Mobilization of Autologous Peripheral Blood Stem Cells (PBSCs), Defined as Cell Yield ≥ 3 x 10e6 CD34+/kg
时间窗: 2 years
Outcome was not reported. The study was terminated for lack of enrollment. Data collection was terminated. No data analysis was performed.
次要结局
- Assess the Per-patient Costs Related to Pegfilgrastim Use in the Mobilization of Autologous PBSCs in 16 Study Participants.(At each stage of pheresis for each enrolled subject for a maximum of 2 years.)
研究者
John M. Hill, Jr., MD
Director, Allogeneic Bone Marrow Transplant Program
Dartmouth-Hitchcock Medical Center
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Improving the health, wellbeing and social networks by of older adults with intellectual disability: The Matilda StudyOlder adults with intellectual disabilityMental and Behavioural DisordersISRCTN15294181lster University64
已完成
不适用
A clinical feasibility study to evaluate the effectiviness and safety of VivescOs TM as bone graft for reconstruction of intra-oral osseous defects.NL-OMON24005Isotis, Bilthoven, the Netherlands10
已完成
不适用
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic FibrosisCystic Fibrosis Related DiabetesPancreatic InsufficiencyNCT00763412Arbelaez, Ana Maria31
进行中（未招募）
不适用
Physiotherapy Treatment for Gynecological Cancer Survivors with Urinary IncontinenceGynecologic CancerUrinary IncontinenceNCT03957434Université de Sherbrooke44
已完成
不适用
A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)Intracranial AneurysmNCT02609867Yonsei University10